Beta
225235

Outcome of Elevated Liver Enzymes in Patients with COVID-19 Infection

Article

Last updated: 22 Jan 2023

Subjects

-

Tags

-

Abstract

Abstract Background: Coronavirus disease 2019 (COVID-19) is an infectious pandemic disease caused by severe acute respi-ratory syndrome coronavirus 2 (SARS-CoV-2). In December 2019, in Wuhan city, China, the first case was discovered, and then it spread all over the world . On 12th of March 2020, the World Health Organization (WHO) officially announced COVID-19 as a global pandemic disease. In addition, patients with severe COVID-19 may be more likely to have liver injury than patients with less severe disease or asymptomatic carriers. Hypoalbuminemia is emerging as a consistent risk factor for severe disease, even among patients without chronic illness. Aim of Study: In this study, we aimed at evaluating liver enzymes among COVID-19 patients and analyzing the rela-tionship between the liver enzymes elevations and severity of COVID-19 infection. Patients and Methods: A retrospective study on data collected from patients who presented between February 2021, and June 2021. The study included 200 patients that had confirmed SARS-CoV-2 infection based on positive results on RT-PCR testing. All patients were subjected to full history taking including history of previous liver disease, general examination, and laboratory investigations including: Liver function tests, hepatitis viral markers , RT-PCR for nasopha-ryngeal swab, and CT chest. The participants were categorized into two groups, if abnormal value of LFT > twice the normal ranges (group 1). The group 2, other participants who had normal LFTs. The length of hospital staying, intensive care requirement, and mortality were considered as prognostic indicators. Results: Group 1 (n=61) with elevated LFT and group 2 (n=139) with normal LFT. When investigating basic charac-teristics, the mean age was 55.8±  22.1 and 59.3±18.6 among group 1 and group 2 respectively. The ALT, AST, and TB were significantly higher among group 1 than group 2. There was no statistically significant difference between both groups regarding Hg, and WBCs. The mean hospital staying was statistically significantly higher among group 1. The intensive care requirement was statistically significantly higher among group 1. There was a statistically significant difference between both groups regarding mortality.

DOI

10.21608/mjcu.2021.225235

Keywords

COVID-19, SARS, CoV-2, liver enzyme, Intensive care, aspartate aminotransferase, alanine aminotransferase

Authors

First Name

SHERIF A. ABD EL AZIZ, M.D.;

Last Name

ABDALLAH H. EL-SHAHAT, M.D.

MiddleName

-

Affiliation

-

Email

-

City

-

Orcid

-

First Name

MOHAMED M. HEGAZY, M.D.;

Last Name

MOHAMED Z. ABU-AMER, M.D.

MiddleName

-

Affiliation

-

Email

-

City

-

Orcid

-

First Name

AHMED M. GHAZY, M.D.;

Last Name

AHMED E. KABIL, M.D.

MiddleName

-

Affiliation

-

Email

-

City

-

Orcid

-

First Name

ABDULLAH M. GAAFAR, M.D.;

Last Name

MOHAMED B. YAHIA, M.D.

MiddleName

-

Affiliation

The Departments of Hepatology, Gastroenterology & Infectious Disease*, Chest Diseases** and Clinical Pathology***, Faculty of Medicine, Al-Azhar University

Email

-

City

-

Orcid

-

Volume

89

Article Issue

December

Related Issue

22432

Issue Date

2021-12-01

Receive Date

2021-09-16

Publish Date

2021-12-01

Page Start

2,943

Page End

2,948

Print ISSN

0045-3803

Online ISSN

2536-9806

Link

https://mjcu.journals.ekb.eg/article_225235.html

Detail API

https://mjcu.journals.ekb.eg/service?article_code=225235

Order

85

Publication Type

Journal

Publication Title

The Medical Journal of Cairo University

Publication Link

https://mjcu.journals.ekb.eg/

MainTitle

-

Details

Type

Article

Created At

22 Jan 2023